Pharmacological DNA demethylation: Implications for cancer immunotherapy

Recent studies have demonstrated that DNA demethylation agents can mimic a viral infection by induction of dsRNAs. This viral mimicry leads to an antiviral response mediated by the cytosolic pattern recognition receptor MDA5, followed by MAVS (IPS1) activation, IRF7 nuclear translocation and upregul...

Descripción completa

Detalles Bibliográficos
Autores principales: Roulois, David, Yau, Helen Loo, De Carvalho, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839380/
https://www.ncbi.nlm.nih.gov/pubmed/27141349
http://dx.doi.org/10.1080/2162402X.2015.1090077
_version_ 1782428130790604800
author Roulois, David
Yau, Helen Loo
De Carvalho, Daniel D.
author_facet Roulois, David
Yau, Helen Loo
De Carvalho, Daniel D.
author_sort Roulois, David
collection PubMed
description Recent studies have demonstrated that DNA demethylation agents can mimic a viral infection by induction of dsRNAs. This viral mimicry leads to an antiviral response mediated by the cytosolic pattern recognition receptor MDA5, followed by MAVS (IPS1) activation, IRF7 nuclear translocation and upregulation of type III Interferon and interferon-stimulated genes.
format Online
Article
Text
id pubmed-4839380
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-48393802016-05-02 Pharmacological DNA demethylation: Implications for cancer immunotherapy Roulois, David Yau, Helen Loo De Carvalho, Daniel D. Oncoimmunology Author's View Recent studies have demonstrated that DNA demethylation agents can mimic a viral infection by induction of dsRNAs. This viral mimicry leads to an antiviral response mediated by the cytosolic pattern recognition receptor MDA5, followed by MAVS (IPS1) activation, IRF7 nuclear translocation and upregulation of type III Interferon and interferon-stimulated genes. Taylor & Francis 2015-11-30 /pmc/articles/PMC4839380/ /pubmed/27141349 http://dx.doi.org/10.1080/2162402X.2015.1090077 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Roulois, David
Yau, Helen Loo
De Carvalho, Daniel D.
Pharmacological DNA demethylation: Implications for cancer immunotherapy
title Pharmacological DNA demethylation: Implications for cancer immunotherapy
title_full Pharmacological DNA demethylation: Implications for cancer immunotherapy
title_fullStr Pharmacological DNA demethylation: Implications for cancer immunotherapy
title_full_unstemmed Pharmacological DNA demethylation: Implications for cancer immunotherapy
title_short Pharmacological DNA demethylation: Implications for cancer immunotherapy
title_sort pharmacological dna demethylation: implications for cancer immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839380/
https://www.ncbi.nlm.nih.gov/pubmed/27141349
http://dx.doi.org/10.1080/2162402X.2015.1090077
work_keys_str_mv AT rouloisdavid pharmacologicaldnademethylationimplicationsforcancerimmunotherapy
AT yauhelenloo pharmacologicaldnademethylationimplicationsforcancerimmunotherapy
AT decarvalhodanield pharmacologicaldnademethylationimplicationsforcancerimmunotherapy

Ejemplares similares